Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Impact of preleukemic mutation...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML

Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML

Bibliographic Details
Main Authors: Tracy Murphy, Jinfeng Zou, Georgina S. Daher-Reyes, Andrea Arruda, Vikas Gupta, Caroline J. McNamara, Mark D. Minden, Aaron D. Schimmer, Hassan Sibai, Karen W.L. Yee, Mariam Korulla, Tracy Stockley, Suzanne Kamel-Reid, Dawn Maze, Anne Tierens, Scott V. Bratman, Andre C. Schuh, Steven M. Chan
Format: Article
Language:English
Published: Elsevier 2019-08-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S247395292030625X
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S247395292030625X

Similar Items

  • Induction of AML Preleukemic Fusion Genes in HSPCs and DNA Damage Response in Preleukemic Fusion Gene Positive Samples
    by: Pavol Kosik, et al.
    Published: (2021-03-01)
  • Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia
    by: Tracy Murphy, et al.
    Published: (2023-06-01)
  • Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis
    by: Victoria V. Grunwald, et al.
    Published: (2019-09-01)
  • Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia
    by: Robert Puckrin, et al.
    Published: (2020-01-01)
  • Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy
    by: Jay Y. Spiegel, et al.
    Published: (2017-09-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs